首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1439700

支架 - 全球市場回顧、競爭格局、市場預測（2030）

Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2024-2030年預測期內，全球支架市場規模預計將以5.61%的複合年增長率成長。由於慢性病盛行率增加、老年人口增加、對微創手術的需求增加以及不健康生活方式的增加等因素，預計該市場將在 2024 年至 2024 年期間出現增長。2030 年預測期內的支架市場。

支架市場動態

支架市場的主要驅動因素之一是慢性病盛行率的增加。此外，慢性病盛行率的不斷上升導致全球患者群體的死亡率上升。例如，根據世界衛生組織（WHO）2022年發佈的數據，全球每年有4,100萬人（71%）因慢性病死亡。此外，每年有1500萬人死於30歲至69歲之間，每年有1790萬人死於心血管疾病，其次是癌症（930萬）、呼吸系統疾病（410萬）和糖尿病（150萬）。估計有10,000,000人）。這四種疾病佔慢性死亡的80%以上。糖尿病患者更容易罹患冠狀動脈疾病和心臟病等心血管疾病。支架也可用於治療胃癌和肺癌等癌症，以及呼吸系統和心血管疾病。因此，這些慢性病的盛行率不斷上升也導致了死亡率的大幅上升。因此，提供支架治療還可以最大限度地減少慢性病導致的死亡率上升，從而促進支架市場的需求和成長。

根據世界衛生組織 (WHO) 2022 年 10 月的數據，2015 年至 2050 年間，60 歲及以上人口將從 12% 至 22% 翻一番，到 2050 年達到 21 億。事實確實如此。此外，到2030年，世界上六分之一的人將超過60歲。 2020 年至 2050 年間，80 歲及以上的人口預計將增加兩倍，達到 4.26 億人。因此，人口老化的增加將導致慢性病的增加。人口老化更有可能患上冠狀動脈疾病等疾病，需要植入支架作為治療方案，這可能會增加需求並促進支架市場的成長。

然而，對支架的嚴格監管審批以及與支架置入相關的併發症可能會減緩支架市場的成長。

此外，持續的 COVID-19 大流行對支架市場產生了負面影響。幾乎所有國家都實施了全國封鎖，限制了人員流動，中斷了供應鍊和物流，由於生產現場缺乏勞動力而降低了生產率，並減少了市場上產品的供應。由於短缺和優先治療COVID-19 患者而被擱置。例如，根據美國醫院協會（2020）的數據，2020 年 3 月至 6 月期間，包括支架置入在內的 "選擇性" 手術的減少估計給美國醫院造成了 507 億美元的損失。據同一消息來源稱，這些程序平均約占美國淨收入的 31%。然而，隨著大規模疫苗接種和封鎖規定的放鬆，供應鏈、物流和製造設備的恢復以及擇期手術的增加，支架市場已恢復動力，預計在預測期內將進一步成長。

支架細分市場分析

就支架市場的產品類型細分而言，預計2022年冠狀動脈支架將佔最高佔有率。為了避免冠狀動脈阻塞引起的心臟疾病，引入支架來治療動脈阻塞。根據世界衛生組織2022年數據，2019年全球約有1,790萬人因心血管疾病死亡。在 1700 萬人過早死亡（70 歲以下）中，38% 是由於心血管疾病。因此，由於心血管疾病的盛行率不斷增加，死亡率也不斷上升。因此，透過提供冠狀動脈支架治療，可以抑制這些心血管疾病導致的死亡率，這將引起冠狀動脈支架市場的成長，並帶動2024年至2030年整體支架市場的成長。

本報告提供了全球支架市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

推動支架市場的因素
- 慢性病盛行率不斷上升
- 老年人口增加
- 支架相關技術的進步
- 久坐的生活方式盛行
支架市場的限制因素與挑戰
- 支架的嚴格監管審批
- 與支架植入相關的併發症
支架市場機遇
- 藥物洗脫支架的需求不斷增加
- 支架開發中 3D 列印的進展

第5章支架市場波特五力分析

第6章COVID-19對支架市場的影響分析

第7章支架市場佈局

依產品類型
- 冠狀動脈
- 靜脈
- 膽道
- 週邊血管
- 其他
依材料類型
- 聚合物
- 合金
- 金屬
依類型
- 自膨脹支架
- 球囊擴張支架
依最終使用者類型
- 醫院
- 門診手術中心
按地區
- 北美
- 歐洲
- 亞太地區
- 其他領域

第 8 章支架市場：全球公司佔有率分析 - 3 至 5 家主要公司

第9章支架市場企業及產品概況

Boston Scientific Corporation
BD
Medtronic
Abbott
Cook
Merit Medical Systems
Novatech SA
Terumo Europe NV
MicroPort Scientific Corporation
Fuji Systems Corp
MICRO-TECH EUROPE
Vascular Concepts
Olympus America
W. L. Gore & Associates Inc
B. Braun Melsungen AG
BIOTRONIK SE & Co. KG
Teleflex Incorporated
Elixir Medical Corporation
REVA Medical, LLC

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0542

Stents Market By Product Type (Coronary, Venous, Biliary, Peripheral And Others), By Material Type (Polymer, Alloy And Metal), By Type (Self-Expanding And Balloon-Expandable Stents), By End-User Type (Hospitals And Ambulatory Surgical Centers, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of chronic diseases and rise in geriatric population.

Global stents market is estimated to grow at a CAGR of 5.61% during the forecast period from 2024 to 2030. The stents market is witnessing a positive growth owing to the factors such as increasing prevalence of chronic diseases, rise in geriatric population, increasing demand of minimally invasive procedures, increase in unhealthy lifestyle, thereby all factors contributing to the growth of stents market during the forecast period from 2024-2030.

Stents Market Dynamics:

One of the main drivers of the stents market is the increasing prevalence of chronic diseases. Furthermore, the rise in the prevalence of chronic diseases will lead to an increase in the mortality rate among the patient population globally. For instance, according to the dada published by World Health Organization (WHO) in 2022, each year 41 million or 71% deaths globally takes place due to chronic diseases. Further, it is estimated that 15 million people aged 30-69 years die each year, 17.9 million die due to cardiovascular diseases annually, followed by cancer (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). All these four diseases account for over 80% of all chronic deaths. People living with diabetes are more prone to cardiovascular diseases such as coronary artery disease, heart attack, and others. Moreover, stents can be used to treat cancers such as stomach, lung and others as well as respiratory and cardiovascular diseases. Therefore, owing to a rise in the prevalence of these chronic diseases, the death rate is also increasing significantly. Thus, by providing the treatment with the help of stents, the mortality rate that is increasing as a result of chronic diseases can also be minimized, thereby driving the demand and growth of stents market.

Moreover, another key factor which is responsible for the growth of stents market is rise in geriatric population, according to World Health Organization (WHO) October 2022 data, it was estimated that between year 2015-2050 people of age 60 and above will be doubled from 12-22% and will reach 2.1 billion by 2050. Further, by 2030, 1 in 6 people in the world will age 60 years or above. The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Therefore, rise in geriatric population will lead to rise in chronic diseases as this population have more chances of getting diseases such as coronary artery diseases and others which require implantation of stents as their treatment solution, which can enhance the growth of stents market as the demand will rise.

However, stringent regulatory approvals for stents and complications associated with implantation of stents can slow down the stents market growth.

Additionally, the ongoing COVID-19 pandemic has negatively impacted the stents market. The nationwide lockdown in almost every country, restricted the movement of people, supply chains & logistics were halted, unavailability of the workforce at the production sites hampered the manufacturing rate due to which there was product shortage in the market, elective surgeries were not given priority as COVID-19 patients were given more preference in terms of treatment. For instance, as per the American Hospital Association 2020, in between March and June 2020, there had been an estimated loss of USD 50.7 billion to the United States hospitals as a result of the reduction observed in "elective" procedures including stents implantation. As per the same source, on an average these procedures had accounted to about 31% of the net revenue in the United States. However, with masses being vaccinated, relaxation in lockdown restrictions, resumption of supply chains, logistics, and manufacturing units, increase in the elective surgeries, the stents market has picked momentum and is expected to further grow during the forecast period.

Stents Market Segment Analysis:

Stents market by Product Type (Coronary, Venous, Biliary and Peripheral, Others), by Material Type (Polymer, Alloy and Metal ), by Type (Self-Expanding and Balloon-Expandable Stents), by End-User Type (Hospitals, Ambulatory Surgical Centers, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In by product type segment of stents market, coronary stents are estimated to hold highest share in year 2022, to avoid the heart attack which is caused due to blockage of coronary arteries, stents can be introduced to treat blocked arteries. According to WHO 2022 data, in 2019 approximately 17.9 million people died due to cardiovascular diseases globally. Out of 17 million premature death (people of age under 70), 38% deaths were caused due to cardiovascular diseases. Therefore, due to increasing prevalence of cardiovascular diseases, death rate is also increasing. Thus, providing treatment with the help of coronary stents, mortality rate due to these cardiovascular diseases can be limited, this induces the growth of coronary stents market leading to the growth of overall stents market forcast during (2024-2030).

The rising approval and launch of coronary stent will alos promote the demand of stents, leading to an overall growth of the stents market, for instance, in September 2022, BIOTRONIK, a leading medical device company, announced U.S. Food and Drug Administration (FDA) approval of its Orsiro® mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES) in the US.

Therefore, increasing prevalence of cardiovascular diseases and approval & launch of coronary stents, increases the stents demand thereby, driving the growth of the overall stents market during the forecast period from 2024-2030.

North America is expected to dominate the overall Stents Market:

Among all the regions, North America is estimated to dominate the global stents market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as rising prevalence of sedentary lifestyle and rising technological advancements associated with the stents increases the stents market in North America.

According to Centers For Disease Control and Prevention (CDC) January 2022 data, in 2022, 25% of the US adults population were found to be physically inactive. In 2020, more then 15% adults were physically inactive. Therefore, rising prevalence of sedentary lifestyle enhance the risk of developing diseases such as diabetes, cancer and others among the US population which require stents as a treatment solution ultimately increase the demand of stents thereby, propelling the growth of stents market in North America.

Furthermore, technological advancements also driving the growth of stents market. For instance, in August 2019, FDA approved treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents are approved to treat obstructed lesions in arteries of the legs.

Further, in January 2020, FDA Approved 3D-printed airway stents developed by Cleveland Clinic doctor, these stents are used to keep the airways open of patients having serious disorders, such as tumors, inflammation, trauma or other masses.

Thus, all above mentioned factors wil surge the demand of stents thereby, driving the growth of the overall stents market during the forecast period from 2024-2030.

Stents Market Key Players:

Some of the key market players operating in the stents market include Boston Scientific Corporation, BD, Medtronic, Abbott, Cook, Merit Medical Systems, Novatech SA, Terumo Europe NV, MicroPort Scientific Corporation, Fuji Systems Corp, MICRO-TECH EUROPE, Vascular Concepts, Olympus America, W. L. Gore & Associates, Inc, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Teleflex Incorporated, Elixir Medical Corporation, REVA Medical, LLC, among others.

Recent Developmental Activities in the Stents Market:

In June 2022, Abbott, a global healthcare leader announced its XIENCE family of stents has received FDA approval for one-month DAPT labeling for high bleeding risk (HBR) patients in the U.S

In October 2020, Medtronic plc, a global leader in medical technology, announced that it has received FDA approval for the Abre(TM) venous self-expanding stent system in U.S for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction

In March 2019, BD, a leading global medical technology company, received U.S. FDA premarket approval for first venous stent to treat iliofemoral venous occlusive disease

Key Takeaways from the Stents Market Report Study:

Market size analysis for current stents market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the stents.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the global stents.
Various opportunities available for the other competitor in the stents market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current stents market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for stents market growth in the coming future?

Target Audience who can be benefited from this Stents Market Report Study

Stents products providers
Research organizations and consulting companies
Stents-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in stents
Various End-users who want to know more about the stents market and latest technological developments in the stents

Frequently Asked Questions for Stents Market:

1. What are Stents?

Stents are tiny metal or plastic tubes which are inserted in a blocked passageway to keep it open. Depending on where it is placed stent restores the flow of blood or other fluids.

2. What is the market for Global Stents?

Global stents market is estimated to grow at a CAGR of 5.61% during the forecast period from 2024 to 2030.

3. What are the drivers for the Global Stents Market?

The stents market is witnessing a positive market growth owing to the factors such as, increasing prevalence of chronic diseases, rise in geriatric population, increasing demand of minimally invasive procedures, increase in unhealthy lifestyle, surge in sedentary lifestyle, technological advancements in product offerings.

4. Who are the key players operating in the Stents Market?

5. Which region has the highest share in Stents Market?

North America is estimated to dominate the global stents market. Factors contributing to the growth of stents market includes rising prevalence of sedentary lifestyle, increasing product approval in the region, and rising technological advancements associated with the stents are drivgn the North America stents market.

1.Stents Market Report Introduction

2.Stents Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The US
3.2. Europe
3.3. Japan
3.4. China

4. Stents Market Key Factors Analysis

4.1. Stents Market Drivers
- 4.1.1. Increasing Prevalence of Chronic Diseases
- 4.1.2. Rise in Geriatric Population
- 4.1.3. Rising Technological Advancements Associated with the Stents
- 4.1.4. Rising Prevalence of Sedentary Lifestyle
4.2. Stents Market Restraints And Challenges
- 4.2.1. Stringent Regulatory Approvals for Stents
- 4.2.2. Complications Associated With Implantation of Stents
4.3. Stents Market Opportunities
- 4.3.1. Growing Demand of Drug-Eluting Stents
- 4.3.2. 3D Printing Advancements in Development of Stents

5. Stents Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Stents Market

7. Stents Market Layout

7.1. By Product Type
- 7.1.1. Coronary
- 7.1.2. Venous
- 7.1.3. Biliary
- 7.1.4. Peripheral
- 7.1.5. Others
7.2. By Material Type
- 7.2.1. Polymer
- 7.2.2. Alloy
- 7.2.3. Metal
7.3. By Type
- 7.3.1. Self-Expanding Stents
- 7.3.2. Balloon-Expanding Stents
7.4. By End User Type
- 7.4.1. Hospitals
- 7.4.2. Ambulatory Surgical Centers
- 7.4.3. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. North America Stents Market, by Country
  - 7.5.1.1.1. US
  - 7.5.1.1.2. Canada
  - 7.5.1.1.3. Mexico
- 7.5.2. Europe
  - 7.5.2.1. Europe Stents Market, by Country
  - 7.5.2.1.1. France
  - 7.5.2.1.2. Germany
  - 7.5.2.1.3. United Kingdom
  - 7.5.2.1.4. Italy
  - 7.5.2.1.5. Spain
  - 7.5.2.1.6. Russia
  - 7.5.2.1.7. Rest of Europe
- 7.5.3. Asia-Pacific
  - 7.5.3.1. Asia-Pacific Stents Market, by Country
  - 7.5.3.1.1. China
  - 7.5.3.1.2. Japan
  - 7.5.3.1.3. India
  - 7.5.3.1.4. Australia
  - 7.5.3.1.5. South Korea
  - 7.5.3.1.6. Rest of Asia Pacific
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. RoW Stents Market, by Region
  - 7.5.4.1.1. Middle East
  - 7.5.4.1.2. Africa
  - 7.5.4.1.3. South America

8. Stents Market Global Company Share Analysis - Key 3-5 Companies

9. Stents Market Company and Product Profiles

9.1. Boston Scientific Corporation
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2. BD
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3. Medtronic
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4. Abbott
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5. Cook
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6. Merit Medical Systems
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7. Novatech SA
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8. Terumo Europe NV
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9. MicroPort Scientific Corporation
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10. Fuji Systems Corp
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11. MICRO-TECH EUROPE
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12. Vascular Concepts
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13. Olympus America
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14. W. L. Gore & Associates Inc
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy
9.15. B. Braun Melsungen AG
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4. Product Listing
- 9.15.5. Entropy
9.16. BIOTRONIK SE & Co. KG
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4. Product Listing
- 9.16.5. Entropy
9.17. Teleflex Incorporated
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4. Product Listing
- 9.17.5. Entropy
9.18. Elixir Medical Corporation
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4. Product Listing
- 9.18.5. Entropy
9.19. REVA Medical, LLC,
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4. Product Listing
- 9.19.5. Entropy